Applied Finance Capital Management LLC Grows Holdings in Stryker Corporation $SYK

Applied Finance Capital Management LLC boosted its holdings in Stryker Corporation (NYSE:SYK) by 19.8% during the first quarter, Holdings Channel.com reports. The firm owned 35,637 shares of the medical technology company’s stock after acquiring an additional 5,895 shares during the quarter. Applied Finance Capital Management LLC’s holdings in Stryker were worth $11,710,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Paradiem LLC boosted its holdings in Stryker by 0.7% in the first quarter. Paradiem LLC now owns 30,941 shares of the medical technology company’s stock worth $10,167,000 after acquiring an additional 229 shares in the last quarter. Procyon Advisors LLC increased its holdings in Stryker by 1.8% in the 1st quarter. Procyon Advisors LLC now owns 5,229 shares of the medical technology company’s stock worth $1,718,000 after buying an additional 91 shares in the last quarter. Financial Advisory Partners LLC raised its position in Stryker by 1.4% in the 1st quarter. Financial Advisory Partners LLC now owns 10,541 shares of the medical technology company’s stock worth $3,464,000 after buying an additional 147 shares during the last quarter. LGT Fund Management Co Ltd. raised its position in Stryker by 170.7% in the 1st quarter. LGT Fund Management Co Ltd. now owns 26,137 shares of the medical technology company’s stock worth $8,588,000 after buying an additional 16,483 shares during the last quarter. Finally, Anchor Investment Management LLC lifted its stake in Stryker by 1.0% during the 1st quarter. Anchor Investment Management LLC now owns 9,499 shares of the medical technology company’s stock valued at $3,121,000 after acquiring an additional 94 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the transaction, the vice president owned 177 shares in the company, valued at approximately $50,170.65. This represents a 95.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 323,264 shares of company stock worth $100,659,489. Company insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of research analyst reports. Citigroup reduced their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Leerink Partners cut their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Argus set a $370.00 price target on shares of Stryker in a research report on Thursday. Evercore set a $350.00 price objective on shares of Stryker in a research note on Monday, July 6th. Finally, Barclays cut their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $392.87.

Stryker Trading Up 0.0%

SYK stock opened at $329.86 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The company has a market capitalization of $126.46 billion, a price-to-earnings ratio of 38.18, a PEG ratio of 2.11 and a beta of 0.77. The business has a 50 day simple moving average of $310.12 and a two-hundred day simple moving average of $337.84. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts anticipate that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s payout ratio is currently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.